The National Cancer Institute (NCI) seeks parties to license software for modeling the targeted delivery of anti-cancer agents in solid tumors.
The software models the permeability and concentration of intravenously administered antibody anti-cancer agent conjugates in solid tumors. The models can be used to determine optimal dosing regimen of a therapeutic in a particular cancer type. Thirty factors that affect delivery rates and efficiencies are analyzed as variables in generating the models.
- Accurate permeability modeling of anti-cancer therapeutics.
- Drug design
- Combination therapy
- Personalized medicine